According to Feuerstein on Ponatinib: 54% major cytogenic response up from 47% in December 70% major cytogenic response up from 65% in the T315 subgroup Pancreatitis unchanged at 6% Full report in the AM. Good luck to the Ariad holders (and the non-Ariad holders as well) on the BV board.